495 related articles for article (PubMed ID: 17349808)
1. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
Salum Lde B; Polikarpov I; Andricopulo AD
J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
[TBL] [Abstract][Full Text] [Related]
2. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity.
Salum LB; Polikarpov I; Andricopulo AD
J Chem Inf Model; 2008 Nov; 48(11):2243-53. PubMed ID: 18937440
[TBL] [Abstract][Full Text] [Related]
3. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors.
Castilho MS; Postigo MP; de Paula CB; Montanari CA; Oliva G; Andricopulo AD
Bioorg Med Chem; 2006 Jan; 14(2):516-27. PubMed ID: 16203153
[TBL] [Abstract][Full Text] [Related]
4. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
Honorio KM; Garratt RC; Andricopulo AD
Bioorg Med Chem Lett; 2005 Jun; 15(12):3119-25. PubMed ID: 15893927
[TBL] [Abstract][Full Text] [Related]
5. Insights into the molecular requirements for the anti-obesity activity of a series of CB1 ligands.
Weber KC; De Lima EF; De Mello PH; Da Silva AB; Honório KM
Chem Biol Drug Des; 2010 Oct; 76(4):320-9. PubMed ID: 20887613
[TBL] [Abstract][Full Text] [Related]
6. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators.
Honório KM; Garratt RC; Polikarpov I; Andricopulo AD
J Mol Graph Model; 2007 Mar; 25(6):921-7. PubMed ID: 17055759
[TBL] [Abstract][Full Text] [Related]
7. Computational studies of TGF-βRI (ALK-5) inhibitors: analysis of the binding interactions between ligand-receptor using 2D and 3D techniques.
Araujo SC; Maltarollo VG; Honorio KM
Eur J Pharm Sci; 2013 Jul; 49(4):542-9. PubMed ID: 23727056
[TBL] [Abstract][Full Text] [Related]
8. Quantitative structure-activity relationships for a series of selective estrogen receptor-beta modulators.
Salum LB; Polikarpov I; Andricopulo AD
SAR QSAR Environ Res; 2007; 18(7-8):711-27. PubMed ID: 18038369
[TBL] [Abstract][Full Text] [Related]
9. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
11. Comparison of estrogen receptor alpha and beta subtypes based on comparative molecular field analysis (CoMFA).
Xing L; Welsh WJ; Tong W; Perkins R; Sheehan DM
SAR QSAR Environ Res; 1999; 10(2-3):215-37. PubMed ID: 10491851
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
[TBL] [Abstract][Full Text] [Related]
13. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
Kulkarni SS; Patel MR; Talele TT
Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR CoMFA studies on bis-coumarine analogues as urease inhibitors: a strategic design in anti-urease agents.
Zaheer-ul-Haq ; Lodhi MA; Ahmad Nawaz S; Iqbal S; Mohammed Khan K; Rode BM; Atta-ur-Rahman ; Choudhary MI
Bioorg Med Chem; 2008 Mar; 16(6):3456-61. PubMed ID: 18280742
[TBL] [Abstract][Full Text] [Related]
15. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
[TBL] [Abstract][Full Text] [Related]
16. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
Zhang H; Li H; Ma Q
J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
[TBL] [Abstract][Full Text] [Related]
17. Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
Wiese TE; Polin LA; Palomino E; Brooks SC
J Med Chem; 1997 Oct; 40(22):3659-69. PubMed ID: 9357533
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
[TBL] [Abstract][Full Text] [Related]
19. 3D QSAR studies of 1,3,4-benzotriazepine derivatives as CCK2 receptor antagonists.
Kaur K; Talele TT
J Mol Graph Model; 2008 Nov; 27(4):409-20. PubMed ID: 18774323
[TBL] [Abstract][Full Text] [Related]
20. Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFalpha modulators.
Avila CM; Romeiro NC; da Silva GM; Sant'Anna CM; Barreiro EJ; Fraga CA
Bioorg Med Chem; 2006 Oct; 14(20):6874-85. PubMed ID: 16843662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
